AOD-9604 5 mg

AOD-9604 (also written AOD 9604) is a synthetic 16-residue research peptide derived from the C-terminal region of human growth hormone (HGH(177-191)), modified with an additional tyrosine residue at the N-terminus. It is supplied as an investigational laboratory peptide for use in HGH C-terminal fragment research, lipid-metabolism research, and structure–activity studies on engineered N-terminally extended HGH-derived peptides.

Laboratory research studies have positioned AOD-9604 as a reference compound for examining how the C-terminal lipolytic domain of HGH engages adipose-tissue research models independent of the growth-hormone-receptor IGF-1 axis. Research models have investigated its receptor-independent engagement, β3-adrenergic receptor expression dynamics, and downstream lipid-metabolism signaling, providing comparative data versus full-length HGH and other HGH-fragment research peptides (Ng et al., 2000, Hormone Research).

Beyond receptor-independent engagement, AOD-9604 is investigated in cellular and animal research models that explore lipid-metabolism research, adipose-tissue research models, chondrocyte research, and cartilage-matrix research. The molecule's N-terminal tyrosine extension, which distinguishes it from the unmodified HGH(177-191) fragment and supports altered physicochemical and receptor-engagement properties, is also a frequent subject of structure–activity and engineered-fragment research.

The peptide is supplied as a lyophilized powder to ensure optimal stability during storage and handling.

Human growth hormone (HGH) is a 191-residue polypeptide that engages the growth-hormone receptor and the prolactin receptor and participates in somatotropic-axis research. Early structure–activity research on HGH demonstrated that distinct functional domains within the full-length molecule could be isolated and synthesized as shorter peptides, including the C-terminal region spanning residues 177-191, which became a focal point in lipid-metabolism research.

AOD-9604 was developed as a synthetic 16-residue analog of HGH(177-191) with an additional tyrosine residue at the N-terminus. This N-terminal extension was engineered to confer altered physicochemical properties and to support comparative research on the lipid-metabolism-associated activity of the HGH C-terminal domain independent of the full-length molecule's growth-hormone-receptor engagement.

This structural design has made AOD-9604 a widely studied reference compound for laboratory investigations of HGH C-terminal fragment pharmacology, β3-adrenergic receptor expression dynamics, and downstream lipid-metabolism signaling. Research interest spans adipose-tissue research models, chondrocyte and cartilage-matrix research, and comparative pharmacology with full-length HGH and the unmodified HGH(176-191) fragment.

1. Receptor-Independent Engagement of Lipid-Metabolism Pathways

AOD-9604 is investigated in research models for its engagement of lipid-metabolism pathways independent of the growth-hormone receptor and the downstream IGF-1 axis. Research models indicate that this receptor-independent engagement modulates adipose-tissue research model signaling and provides a structurally focused tool for examining the C-terminal HGH lipid-metabolism domain.

2. Modulation of β3-Adrenergic Receptor Expression

Laboratory research studies have characterized AOD-9604 as modulating β3-adrenergic receptor expression in adipose-tissue research models. This dynamic is investigated as a contributor to altered downstream lipid-metabolism signaling and is an active area of structure–activity research on the engineered N-terminally extended HGH C-terminal fragment.

3. Lipid-Metabolism Signaling Without Growth-Hormone-Receptor Engagement

Laboratory research studies have characterized AOD-9604 as modulating adipose-tissue research model lipid-metabolism signaling without engaging the growth-hormone receptor or modulating downstream IGF-1 production. This receptor-selectivity profile is an active area of structure–activity research and is investigated as a distinguishing feature relative to full-length HGH in laboratory comparative studies.

4. Chondrocyte and Cartilage-Matrix Research

Research models have investigated AOD-9604 in chondrocyte research and cartilage-matrix research, examining its engagement of collagen and proteoglycan biosynthesis pathways in cartilage-tissue research models. This research direction is a frequent subject of HGH-fragment comparative pharmacology and structure–activity research.

Research Applications

Conclusion

AOD-9604 represents a structurally engineered HGH C-terminal fragment with an N-terminal tyrosine extension that has become a reference compound in HGH C-terminal fragment research. Its combination of receptor-independent engagement of lipid-metabolism pathways, modulation of β3-adrenergic receptor expression, and absence of growth-hormone-receptor engagement makes it a valuable investigational laboratory peptide for studying HGH-fragment pharmacology and structure–activity research models.

Research Use Disclaimer

This product is intended for research and laboratory use only. It is designed exclusively for in vitro research purposes. All information provided is for educational and research reference only. This product is not intended for human or animal use. It is not a drug, food, or cosmetic and must not be marketed, labeled, or used as such. Use and handling are restricted to trained and qualified professionals.